# EDGAR Filing Document

**Accession Number:** 0001832106
**File Stem:** 0001493152-25-020081
**Filing Date:** 2025-10
**Character Count:** 21773
**Document Hash:** fae61b52d956e87cac0b09ca4274e721
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-020081.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001493152-25-020081

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProMIS Neurosciences Inc.
- **CENTRAL INDEX KEY:** 0001374339
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93797
- **FILM NUMBER:** 251430435

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2
- **BUSINESS PHONE:** 416-847-6898

**MAIL ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMORFIX LIFE SCIENCES LTD
- **DATE OF NAME CHANGE:** 20060831
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABG Management Ltd.
- **CENTRAL INDEX KEY:** 0001832106

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 15 QUEENS ROAD CENTRAL, UNIT 3002-3004
- **STREET 2:** 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK
- **CITY:** HONG KONG
- **STATE:** F4
- **ZIP:** 0000000000
- **BUSINESS PHONE:** 852 31219699

**MAIL ADDRESS:**
- **STREET 1:** 15 QUEENS ROAD CENTRAL, UNIT 3002-3004
- **STREET 2:** 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK
- **CITY:** HONG KONG
- **STATE:** F4
- **ZIP:** 0000000000

## Ex-1

**Exhibit 1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of October 29, 2025.

---

| | |
|:---|:---|
| **ABG Management Ltd.** | **ABG Management Ltd.** |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **Ally Bridge Group (NY) LLC** | **Ally Bridge Group (NY) LLC** |
| By: ABG Management Ltd., its managing member | By: ABG Management Ltd., its managing member |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **Ally Bridge MedAlpha Master Fund L.P.** | **Ally Bridge MedAlpha Master Fund L.P.** |
| By: Ally Bridge Group (NY) LLC, its manager | By: Ally Bridge Group (NY) LLC, its manager |
| By: ABG Management Ltd., its managing member | By: ABG Management Ltd., its managing member |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| Fan Yu | Fan Yu |
| /s/ Fan Yu | /s/ Fan Yu |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**ProMIS Neurosciences Inc.**

*(Name of Issuer)*

**Common Shares, no par value per share**

*(Title of Class of Securities)*

**74346M406**

*(CUSIP Number)*

**Fan Yu**<br>c/o ABG Management Ltd.

#3902, 39/F, E Tower, 10 Harcourt RD CTR<br>Hong Kong K3 0000000000<br>852 31219699

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74346M406** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ABG Management Ltd.** | Name of reporting person<br>**ABG Management Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6070405.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6070405.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.3%** | Percent of class represented by amount in Row (11)<br>**11.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **74346M406** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ally Bridge Group (NY) LLC** | Name of reporting person<br>**Ally Bridge Group (NY) LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6070405.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6070405.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.3%** | Percent of class represented by amount in Row (11)<br>**11.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Limited Liability Company

| **CUSIP No.** | **74346M406** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ally Bridge MedAlpha Master Fund L.P.** | Name of reporting person<br>**Ally Bridge MedAlpha Master Fund L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6070405.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6070405.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.3%** | Percent of class represented by amount in Row (11)<br>**11.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **74346M406** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fan Yu** | Name of reporting person<br>**Fan Yu** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**O1** | Citizenship or place of organization<br>**O1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6070405.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6070405.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | Aggregate amount beneficially owned by each reporting person<br>**6070405.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.3%** | Percent of class represented by amount in Row (11)<br>**11.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, no par value per share

**(b) Name of Issuer:**
ProMIS Neurosciences Inc.

**(c) Address of Issuer's Principal Executive Offices:**
Suite 200, 1920 Yonge Street, Toronto, A6, M4S 3E2

**Item 4. Purpose of Transaction**

Director Appointment

On October 22, 2025, the Issuer announced that Slanix Paul Alex, the President and Portfolio Manager, of Public Equity at Ally Bridge Group, was appointed to the Issuer's Board of Directors (the "Board") effective immediately.

Registration Rights Agreements

On August 21, 2023, the Issuer entered into a Unit Purchase Agreement (the "2023 Unit Purchase Agreement") with the Reporting Persons and other selected investors. Pursuant to the terms of the 2023 Unit Purchase Agreement, the Reporting Persons purchased warrants to purchase Common Shares. In connection with the 2023 Unit Purchase Agreement, the Reporting Persons entered into a Registration Rights Agreement (the "2023 Registration Rights Agreement") with the Issuer pursuant to which the Issuer filed a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the Common Shares underlying the securities purchased pursuant to the 2023 Unit Purchase Agreement.

On July 26, 2024, the Issuer entered into a Unit Purchase Agreement (the "2024 Unit Purchase Agreement") with the Reporting Persons and other selected investors. Pursuant to the terms of the 2024 Unit Purchase Agreement, the Reporting Persons purchased warrants to purchase Common Shares. In connection with the 2024 Unit Purchase Agreement, the Reporting Persons entered into a Registration Rights Agreement (the "2024 Registration Rights Agreement") with the Issuer pursuant to which the Issuer filed a registration statement with the SEC covering the resale of the Common Shares underlying the securities purchased pursuant to the 2024 Unit Purchase Agreement.

On July 28, 2025, the Issuer entered into a Unit Purchase Agreement (the "2025 Unit Purchase Agreement") with the Reporting Persons and other selected investors. Pursuant to the terms of the 2025 Unit Purchase Agreement, the Reporting Persons purchased warrants to purchase Common Shares. In connection with the 2025 Unit Purchase Agreement, the Reporting Persons entered into a Registration Rights Agreement (the "2025 Registration Rights Agreement") with the Issuer pursuant to which the Issuer filed a registration statement with the SEC covering the resale of the Common Shares underlying the securities purchased pursuant to the 2025 Unit Purchase Agreement.

The foregoing descriptions of the 2023 Registration Rights Agreement, the 2024 Registration Rights Agreement and the 2025 Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreement, each of which is attached as an exhibit to this Schedule 13D and incorporated herein by reference.

General

The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may engage in discussions with management, the Board, and securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Common Shares; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the Board. To facilitate their consideration of such matters, the Reporting Persons may retain consultants and advisors and may enter into discussions with potential sources of capital and other third parties. The Reporting Persons may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Persons will likely take some or all of the foregoing steps at preliminary stages in their consideration of various possible courses of action before forming any intention to pursue any particular plan or direction.

Other than as described above, the Reporting Persons do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained on the cover pages is incorporated by reference into this Item 5.

The ownership information presented herein represents beneficial ownership of the Issuer's Common Shares, based on 53,811,110 Common Shares outstanding as of September 26, 2025, as disclosed in the Issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on October 3, 2025.

The Common Shares reported as beneficially owned herein include: (i) 6,058,738 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., and (ii) 11,667 Common Shares underlying an employee stock option granted to Dr. Alex by the Issuer and held by him for the benefit of Ally Bridge MedAlpha Master Fund L.P., which amount represents the number of Common Shares that are currently vested or that will vest within 60 days of the date of this filing. The amount of securities reported herein does not include 9,690,037 Common Shares issuable upon exercise of warrants held of record by Ally Bridge MedAlpha Master Fund L.P., which are subject to limitations on exercise.

Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. Each of them disclaims beneficial ownership of such securities.

**(b)**
The information contained on the cover pages is incorporated by reference into this Item 5.

**(c)**
The Reporting Persons have not effected any transactions in the Common Shares during the past sixty days.  On October 22, 2025, Dr. Alex was granted an employee stock option to purchase 40,000 Common Shares.  Twenty-five percent of the shares subject to this option vested on the date of grant and the remaining shares will vest in thirty-six equal monthly installments thereafter, subject to Dr. Alex's continued service as a director on each such vesting date.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 4 above summarizes certain provisions of the 2023 Registration Rights Agreement, the 2024 Registration Rights Agreement and the 2025 Registration Rights Agreement and are incorporated herein by reference. A copy of each such agreement is attached as an exhibit to this Schedule 13D and is incorporated herein by reference.

Except as set forth herein, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ABG Management Ltd.

**Signature:** By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 10/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ally Bridge Group (NY) LLC

**Signature:** By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 10/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ally Bridge MedAlpha Master Fund L.P.

**Signature:** By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 10/29/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fan Yu

**Signature:** /s/ Fan Yu

**Name/Title:** Fan Yu

**Date:** 10/29/2025